Anaptysbio Depreciation & Amortization Growth & History (ANAB)
Anaptysbio's depreciation and amortization was $559,000 for fiscal 2025.
View full Anaptysbio company overviewAnaptysbio annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $559,000 | −$47,000 | −7.76% |
| 2024 | 2024-12-31 | $606,000 | −$46,000 | −7.06% |
| 2023 | 2023-12-31 | $652,000 | −$23,000 | −3.41% |
| 2022 | 2022-12-31 | $675,000 | $56,000 | +9.05% |
| 2021 | 2021-12-31 | $619,000 | $60,000 | +10.73% |
| 2020 | 2020-12-31 | $559,000 | $45,000 | +8.75% |
| 2019 | 2019-12-31 | $514,000 | $199,000 | +63.17% |
| 2018 | 2018-12-31 | $315,000 | $132,000 | +72.13% |
| 2017 | 2017-12-31 | $183,000 | −$50,000 | −21.46% |
| 2016 | 2016-12-31 | $233,000 | −$41,000 | −14.96% |
| 2015 | 2015-12-31 | $274,000 | — | — |
Anaptysbio quarterly depreciation and amortization
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | $130,000 | −$16,000 | −10.96% |
| Q4 2025 | 2025-12-31 | $606,000 | — | — |
| Q3 2025 | 2025-09-30 | $140,000 | −$4,000 | −2.78% |
| Q2 2025 | 2025-06-30 | $142,000 | −$12,000 | −7.79% |
| Q1 2025 | 2025-03-31 | $146,000 | −$17,000 | −10.43% |
| Q3 2024 | 2024-09-30 | $144,000 | −$14,000 | −8.86% |
| Q2 2024 | 2024-06-30 | $154,000 | −$9,000 | −5.52% |
| Q1 2024 | 2024-03-31 | $163,000 | −$3,000 | −1.81% |
| Q3 2023 | 2023-09-30 | $158,000 | −$8,000 | −4.82% |
| Q2 2023 | 2023-06-30 | $163,000 | $0 | 0.00% |
| Q1 2023 | 2023-03-31 | $166,000 | $4,000 | +2.47% |
| Q3 2022 | 2022-09-30 | $166,000 | −$3,000 | −1.78% |
| Q2 2022 | 2022-06-30 | $163,000 | $3,000 | +1.88% |
| Q1 2022 | 2022-03-31 | $162,000 | $37,000 | +29.60% |
| Q3 2021 | 2021-09-30 | $169,000 | $31,000 | +22.46% |
| Q2 2021 | 2021-06-30 | $160,000 | $23,000 | +16.79% |
| Q1 2021 | 2021-03-31 | $125,000 | −$15,000 | −10.71% |
| Q3 2020 | 2020-09-30 | $138,000 | $3,000 | +2.22% |
| Q2 2020 | 2020-06-30 | $137,000 | $13,000 | +10.48% |
| Q1 2020 | 2020-03-31 | $140,000 | $25,000 | +21.74% |
| Q3 2019 | 2019-09-30 | $135,000 | $44,000 | +48.35% |
| Q2 2019 | 2019-06-30 | $124,000 | $60,000 | +93.75% |
| Q1 2019 | 2019-03-31 | $115,000 | $61,000 | +112.96% |
| Q3 2018 | 2018-09-30 | $91,000 | $45,000 | +97.83% |
| Q2 2018 | 2018-06-30 | $64,000 | $13,000 | +25.49% |
| Q1 2018 | 2018-03-31 | $54,000 | $15,000 | +38.46% |
| Q3 2017 | 2017-09-30 | $46,000 | −$12,000 | −20.69% |
| Q2 2017 | 2017-06-30 | $51,000 | −$9,000 | −15.00% |
| Q1 2017 | 2017-03-31 | $39,000 | −$18,000 | −31.58% |
| Q3 2016 | 2016-09-30 | $58,000 | — | — |
| Q2 2016 | 2016-06-30 | $60,000 | — | — |
| Q1 2016 | 2016-03-31 | $57,000 | — | — |
Anaptysbio depreciation and amortization trends
Over the last five fiscal years, Anaptysbio's depreciation and amortization increased from $559,000 to $559,000, a change of $0. The latest reported quarter, Q1 2026, shows $130,000.
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Anaptysbio source filings ↗